As potential factors in lung cancer development, nicotine and NNK can activate both PKC and SRK (i.e., ERK1/2) physiological Bcl2 kinases [5, 37, 44] and inhibit chemotherapeutic drug-induced apoptosis in lung cancer cells [5, 29]. This evidence concerns the gene MAPK3 and lung cancer.